ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 819

Use of Takayasu Arteritis Damage Score (TADS) to Measure Damage in Takayasu Arteritis

Sivakumar Mambakkam Rajappa1 and Krishnamurthy Venkataraman2, 1Rheumatology and Immunology, GLB Hospitals, Chennai, India, 2Rheumatology, Apollo Speciality Hospitals, Chennai, India

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Drug toxicity, large vessel vasculitis, outcomes and takayasu arteritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Vasculitis Poster I: Non-ANCA-Associated and Related Disorders

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose:

Takayasu Arteritis (TA) in India frequently present with complications, indicating the need for a specific damage index to capture the accumulation of disease-related scars over time. Takayasu Arteritis Damage Score (TADS) devised by us is a clinical index for use in these circumstances.

Methods:

Disease extent in TA is assessed using the comprehensive tool, Disease Extent Index for Takayasu Arteritis (DEI.Tak). We modified this established score, using a large database of cases previously assessed by us. Items persisting for more six months, related to accumulating scars, were selected while omitting those used infrequently to produce a shorter form with 42 items focused on CVS, particularly pulse loss and vascular interventions. Drug-related damage were also included. This new TADS form was compared to Vasculitis Damage Index (VDI) and PGO using paper cases. It was then applied to analyze a cohort of 286 cases followed in one clinic over 2 decades.

Results:

The increase in damage/scars over time correlated closely with disease duration, continuing to increase over 20 years. TADS also related to poor outcomes such as pulse loss. In a cohort of 286 TA patients, the mean age at onset of TA symptoms was 33.74 years (8-42). 142 vascular interventions were performed in 102 of this cohort (34 men, 68 women, mean disease duration 8.9 years). The procedures performed were: Carotid angioplasty + stenting – 29, vertebral angioplasty + stenting-6, grafts from ascending aorta to Carotids-4, subclavian angioplasty + stenting- 22, renal angioplasty + stenting-31, Aortic angioplasty + stenting – 15, coronary angioplasty + stenting- 22 and CABG Surgeries-14. The mean follow up period was 144 months. Associated clinical features and drug therapy were recorded. Peri-operative complications included infections- 5.2%, Stroke- 8.8%, Myocardial infarction-4.6% and renal failure-4.8%. Drug toxicity and damage were seen in 30%. There were no deaths due to the procedures and TADS scores continued to rise.. The patency of stents at 5 and 10 years were 92% and 83% respectively. In the majority (84.7%), drug therapy was also continuing. 32/286 patients died and the scores in fatal disease were higher than in non-fatal cases (7.4 Vs 4.8).

Conclusion:

Damage is a significant factor in TA. Vessel occlusion is a major feature of TA, often requiring vascular interventions. Recording the new disease-specific damage score, TADS helps delineate features associated with pulse loss, long-term stent patency, drug induced damage and mortality.


Disclosure: S. Mambakkam Rajappa, None, 1, 2, 3, 4, 5, 6, 7, 8, 9; K. Venkataraman, None.

To cite this abstract in AMA style:

Mambakkam Rajappa S, Venkataraman K. Use of Takayasu Arteritis Damage Score (TADS) to Measure Damage in Takayasu Arteritis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/use-of-takayasu-arteritis-damage-score-tads-to-measure-damage-in-takayasu-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/use-of-takayasu-arteritis-damage-score-tads-to-measure-damage-in-takayasu-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology